Status:
COMPLETED
Memantine and Intensive Speech-Language Therapy in Aphasia
Lead Sponsor:
Gabinete Berthier y Martínez
Collaborating Sponsors:
H. Lundbeck A/S
Conditions:
Aphasia
Stroke
Eligibility:
All Genders
18-69 years
Phase:
PHASE4
Brief Summary
* Aphasia, the loss or impairment of language caused by brain damage, is one of the most devastating cognitive impairments of stroke. Aphasia can be treated with combination of speech-language therapy...
Detailed Description
* The efficacy of drugs that act on glutamate such as the N-methyl-D-aspartic acid (NMDA) receptor antagonist memantine requires to be explored in this population. The rationale for using memantine in...
Eligibility Criteria
Inclusion
- Chronic aphasia of more than one year duration
- Must be able to complete protocol
Exclusion
- Dementia
- Major psychiatric illness
- Severe global aphasia (precludes participation in constraint-induced language therapy)
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2007
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT00640198
Start Date
March 1 2005
End Date
November 1 2007
Last Update
March 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gabinete Berthier y Martínez and Centro de Investigaciones Médico-Sanitarias (CIMES) University of Malaga
Málaga, Malaga, Spain, 29001